Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. A complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests~2. Age greater than or equal to 18 and Age less than or equal to 65 years~3. BMI greater than or equal to 18.5 and BMI less than or equal to 32.0 kg/m2 (Body Mass Index)~4. Signed and dated written informed consent prior to admission to the study~5. Male subjects, or females who meet any of the following criteria from at least 30 days before the first study drug administration and until 30 days after trial completion:~   * Using adequate contraception, e.g. any of the following methods plus condom: implants, injectables, combined oral contraceptives, intrauterine device (IUD)~  * Sexually abstinent~  * Have a vasectomised sexual partner (vasectomy at least one year prior to enrolment)~  * Surgically sterilised (including hysterectomy)~  * Postmenopausal defined as at least one year of spontaneous amenorrhea~Exclusion criteria:~1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal~2. Repeated measurement of supine systolic blood pressure outside the range of 100-140 mm Hg or diastolic blood pressure outside the range of 60-90 mm Hg or pulse less than 55 bpm~3. Any subject with orthostatic hypotension at baseline screening exam~4. Any laboratory value outside the reference range~5. Any evidence of a clinically relevant concomitant disease~6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic (including insulin-dependent diabetes), immunological or hormonal disorders~7. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders (such as depression) or neurological disorders (such as neuropathy)~8. History of relevant orthostatic hypotension, fainting spells or blackouts~9. Chronic or relevant acute infections~10. History of relevant allergy/hypersensitivity~11. Intake of drugs with a long half-life (greater than 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial.~12. Use of drugs which might reasonably influence the results of the trial within 10 days prior to administration or during the trial~13. Participation in another trial with an investigational drug within two months prior to administration or during the trial~14. Any concomitant therapy~15. Smoker~16. History of alcohol abuse~17. History of drug abuse~18. Blood donation~19. Excessive physical activities (within one week prior to administration or during the trial)~20. Subjects should not swim during the treatment periods of the trial~21. Any condition of the skin, including eczema, psoriasis, or lymphedema, that involves the upper arm in the area that would be utilized for application of the treatments~22. Pregnancy or planning to become pregnant within two months of study completion~23. Positive pregnancy test~24. A screening ECG that displays first-degree atrioventricular block (P-R interval \> 0.20 seconds) or other conduction disturbance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Catapres-TTS-3 crossover 1 (Type: EXPERIMENTAL): subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1)
- Catapres-TTS-3 crossover 2 (Type: EXPERIMENTAL): subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1)
- Catapres-TTS-1 crossover 1 (Type: EXPERIMENTAL): subject to receive 0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously

Based on this trial design, predict the completion outcome and termination type (if applicable).